Last reviewed · How we verify

NCT07509541: INSTAB-PE

Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy

Not yet recruiting Last updated 3 April 2026
What this trial tests

trial testing Percutaneous Pulmonary Thrombectomy (FlowTriever) in Pulmonary Embolism Acute in 100 participants. Not yet recruiting.

Timeline
10 April 2026
Primary endpoint
10 April 2030
10 May 2030

Quick facts

Lead sponsorHospital Universitari Vall d'Hebron Research Institute
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment100
Start date10 April 2026
Primary completion10 April 2030
Estimated completion10 May 2030
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Who can join

18 and older, any sex, with Pulmonary Embolism Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pulmonary embolism (PE) is a potentially life-threatening condition caused by the obstruction of pulmonary arteries by thrombi. Patients with high-risk or intermediate-high-risk PE may require immediate reperfusion therapies, including percutaneous pulmonary thrombectomy. However, this procedure can be associated with significant hemodynamic and respiratory instability, potentially leading to shock, cardiac arrest, or the need for advanced support such as mechanical ventilation or extracorporeal membrane oxygenation (ECMO). The mechanisms, timing, and causes of intraprocedural hemodynamic and respiratory deterioration during pulmonary thrombectomy are not well established. Factors such as catheter manipulation within the pulmonary arteries, increased pulmonary pressures, and the effects of anesthesia and mechanical ventilation may contribute to clinical instability. In addition, biomarkers such as NT-proBNP may reflect right ventricular strain and could help predict the risk of instability during the procedure. The aim of this prospective observational study is to determine the incidence, causes, and timing of hemodynamic and/or respiratory instability during percutaneous pulmonary thrombectomy in patients with high-risk or intermediate-high-risk PE. The study will also compare the occurrence of instability between different thrombectomy devices (FlowTriever® and Indigo® systems) and evaluate the prognostic role of baseline NT-proBNP levels. Secondary objectives include the assessment of in-hospital and 30-day mortality and their underlying causes. This study will include adult patients undergoing percutaneous pulmonary thrombectomy as part of routine clinical care. The results of this study may help improve risk stratification, guide procedural planning, and optimize the management of patients undergoing pulmonary thrombectomy, ultimately aiming to reduce morbidity and mortality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pulmonary Embolism Acute

Currently open trials in the same condition.

Other Hospital Universitari Vall d'Hebron Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07509541.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing